BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018. The VP of Marketing, Andrew Flynn, asks about the current treatments for ovarian cancer. David explains that most ovarian cancers spread through the pelvis and into the peritoneum, and surgery remains a good option at the beginning Give an example of a technique that can be used to measure the affinity of the antibody for Factor 801A? Explain how it works. … David adds that an intra-peritoneal (IP) injection would be an ideal treatment for ovarian cancer and asked if any PK studies were done in BALB/c mice with this technique.
BugRx is a new
Give an example of a technique that can be used to measure the affinity of the antibody for Factor 801A? Explain how it works.
…
David adds that an intra-peritoneal (IP) injection would be an ideal treatment for ovarian cancer and asked if any PK studies were done in BALB/c mice with this technique.
Step by step
Solved in 2 steps
